CN107106638A - 具有抗炎特性的肽 - Google Patents

具有抗炎特性的肽 Download PDF

Info

Publication number
CN107106638A
CN107106638A CN201580067933.5A CN201580067933A CN107106638A CN 107106638 A CN107106638 A CN 107106638A CN 201580067933 A CN201580067933 A CN 201580067933A CN 107106638 A CN107106638 A CN 107106638A
Authority
CN
China
Prior art keywords
formula
amino acid
seq
inflammatory
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580067933.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·杰尼斯 杰西
W·洛佩兹 亨利
R·马丁 乔治
克莱顿·耶茨
E·加文 查尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torrent Biological Sciences Ltd
Original Assignee
Torrent Biological Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Biological Sciences Ltd filed Critical Torrent Biological Sciences Ltd
Publication of CN107106638A publication Critical patent/CN107106638A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/10—Bryophyta (mosses)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
CN201580067933.5A 2014-10-14 2015-10-13 具有抗炎特性的肽 Pending CN107106638A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462063909P 2014-10-14 2014-10-14
US62/063,909 2014-10-14
PCT/US2015/055380 WO2016061133A1 (en) 2014-10-14 2015-10-13 Peptides having anti-inflammatory properties

Publications (1)

Publication Number Publication Date
CN107106638A true CN107106638A (zh) 2017-08-29

Family

ID=54365375

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580067933.5A Pending CN107106638A (zh) 2014-10-14 2015-10-13 具有抗炎特性的肽
CN201580067961.7A Expired - Fee Related CN107580502B (zh) 2014-10-14 2015-10-13 用于治疗胰腺癌的基于肽的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580067961.7A Expired - Fee Related CN107580502B (zh) 2014-10-14 2015-10-13 用于治疗胰腺癌的基于肽的方法

Country Status (10)

Country Link
US (5) US10016480B2 (enExample)
EP (2) EP3206703B1 (enExample)
JP (3) JP6613312B2 (enExample)
KR (3) KR20230004907A (enExample)
CN (2) CN107106638A (enExample)
AU (2) AU2015333678B2 (enExample)
BR (1) BR112017007543A2 (enExample)
CA (2) CA2964361A1 (enExample)
WO (2) WO2016061087A1 (enExample)
ZA (1) ZA201702537B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109745324A (zh) * 2017-11-06 2019-05-14 中国科学院上海生命科学研究院 非经典NF-kB通路的小分子抑制剂及其应用
CN112840211A (zh) * 2018-08-27 2021-05-25 南特生物公司 Rp182组合物及方法
CN114207117A (zh) * 2019-04-12 2022-03-18 激流生物科学有限公司 用于调节巨噬细胞活性的方法
CN115838395A (zh) * 2022-11-15 2023-03-24 西北农林科技大学 具有可溶性环氧化物水解酶抑制作用的活性肽及其应用
CN118530299A (zh) * 2023-08-25 2024-08-23 广州益养生物科技有限公司 一种三肽、三肽盐或衍生物及其应用

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3653212B1 (en) 2012-12-20 2023-04-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CA2964361A1 (en) * 2014-10-14 2016-04-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Peptide-based methods for treating pancreatic cancer
WO2017149012A1 (en) * 2016-03-02 2017-09-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides and uses thereof for reducing cd95-mediated cell motility
SG11201807770RA (en) * 2016-03-24 2018-10-30 Nantcell Inc Sequence arrangements and sequences for neoepitope presentation
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
JP7537074B2 (ja) 2016-05-10 2024-08-21 ソルボンヌ ウニベルシテ Ｃｄ４７を活性化する作用物質およびその炎症治療における使用
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TW201803598A (zh) 2016-06-30 2018-02-01 南特細胞公司 Ｎａｎｔ癌症疫苗
CN106432014B (zh) * 2016-09-05 2019-08-16 中国医学科学院放射医学研究所 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用
US10799555B2 (en) 2016-09-15 2020-10-13 Leidos, Inc. PD-1 peptide inhibitors
WO2018086562A1 (en) * 2016-11-09 2018-05-17 Shen Tang Long Method for treatment or prevention of cancer
US20190358263A1 (en) * 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
JP7051898B2 (ja) 2017-04-24 2022-04-11 ナントセル，インコーポレイテッド 標的型ネオエピトープベクター及びそのための方法
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
ES3041991T3 (en) 2017-05-25 2025-11-17 Leidos Inc Pd-1 and ctla-4 dual inhibitor peptides
EP3687559B1 (en) 2017-09-29 2025-11-12 Sanford Burnham Prebys Medical Discovery Institute Compositions that target tumor-associated macrophages and methods of use therefor
AU2019209428B2 (en) 2018-01-22 2025-06-26 Endocyte, Inc. Methods of use for CAR T cells
CA3090089A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
AU2018410849B2 (en) * 2018-02-27 2025-02-27 Leidos, Inc. PD-1 peptide inhibitors
US11823773B2 (en) 2018-04-13 2023-11-21 Nant Holdings Ip, Llc Nant cancer vaccine strategies
US12383537B2 (en) * 2018-06-20 2025-08-12 Universidade De Coimbra (3S)-and (3R)-6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles as P53 activators
EP3836955A4 (en) * 2018-08-15 2022-05-18 The Regents of the University of California IL-10 INHIBITION FOR VACCINES AND IMMUNOTHERAPY
US20220143130A1 (en) * 2018-08-29 2022-05-12 Riptide Bioscience, Inc. Peptides Having Immunomodulatory Properties
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
WO2020046297A2 (en) * 2018-08-29 2020-03-05 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
CN110960679A (zh) * 2018-09-28 2020-04-07 江苏康缘药业股份有限公司 一种抗肿瘤的药物组合物及其应用
US20220053773A1 (en) * 2018-10-01 2022-02-24 Innate Immunity LLC Compositions and methods for the treatment of pathogenic infections in plants
US20200102356A1 (en) * 2018-10-01 2020-04-02 NMC Inc. Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
JP7606471B2 (ja) 2019-05-22 2024-12-25 レイドス， インコーポレイテッド Ｌａｇ３結合ペプチド
US20220125866A1 (en) * 2019-06-28 2022-04-28 Nantcell, Inc Pharmaceutical compositions to enhance phagocytosis without inflammation
CN115768757B (zh) 2019-12-19 2025-07-11 美利坚合众国,由健康及人类服务部部长代表 Cd206调节剂及其用途和制备方法
CN111116713B (zh) * 2020-01-07 2023-06-23 郑州大学 Sirpa蛋白亲和环肽及其应用
EP4100428A4 (en) 2020-02-04 2024-03-06 Seattle Children's Hospital (DBA Seattle Children's Research Institute) CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS
AU2021246017A1 (en) * 2020-03-31 2022-11-10 Innate Immunity LLC Recombinant peptide to treat fire blight
US11338040B2 (en) 2020-06-04 2022-05-24 Leidos, Inc. Immunomodulatory compounds
WO2022034523A1 (en) 2020-08-13 2022-02-17 Immunitybio, Inc. Phagocytosis-inducing compounds and methods of use
WO2022081426A1 (en) 2020-10-12 2022-04-21 Leidos, Inc. Immunomodulatory peptides
EP4365187A4 (en) * 2021-06-28 2025-11-19 Univ Korea Res & Bus Found Peptide with anticancer activity and its use
CN115607674B (zh) * 2021-07-15 2023-09-19 深圳开悦生命科技有限公司 Rna解旋酶dhx33抑制剂在制备用于治疗胰腺癌的药物中的应用
WO2023080578A1 (ko) * 2021-11-05 2023-05-11 주식회사 레메디 상처 치료 및 항염증 활성을 가지는 펩타이드 및 이의 용도
WO2023097111A2 (en) * 2021-11-29 2023-06-01 Riptide Bioscience, Inc. Methods and compositions for treating calcinosis associated conditions
WO2023111695A1 (en) * 2021-12-16 2023-06-22 Ramakrishna Reddy Isanaka A stable anti-angiogenic and anti-inflammatory pharmaceutical formulation and pharmaceutical combination for treatment and prevention of psoriasis
KR102920640B1 (ko) 2022-03-11 2026-01-29 국립순천대학교산학협력단 항진균 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항진균용 조성물
WO2024102993A1 (en) * 2022-11-10 2024-05-16 Research Foundation Of The City University Of New York Cationically-enframed high density aromatic peptides
CN116768970A (zh) * 2023-05-19 2023-09-19 重庆师范大学 抗氧化多肽、制备方法及其应用
WO2025093952A1 (en) * 2023-10-30 2025-05-08 Ramakrishna Reddy Isanaka Peptide with anti-inflammatory and anti-microbial activity
WO2025255373A2 (en) * 2024-06-05 2025-12-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fatty acid and cyclized derivatives of the immunomodulatory peptide rp-182 with improved anti-tumor activity, compositions, and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003749A1 (en) * 1991-08-21 1993-03-04 Board Of Regents, The University Of Texas System Methods and compositions for modulating g protein action
WO1995028832A1 (en) * 1994-04-20 1995-11-02 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
CN1377276A (zh) * 1999-08-09 2002-10-30 特里帕普股份公司 含有三肽的药用组合物
CN101485885A (zh) * 2009-01-09 2009-07-22 中国科学院广州生物医药与健康研究院 蛋白磷酸酯酶PPM1E作为疾病的治疗靶标及其应用和siRNA
US20120270770A1 (en) * 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE127838T1 (de) 1987-07-06 1995-09-15 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
EP1004595B1 (en) 1989-04-10 2003-06-18 Helix BioMedix, Inc. Lytic and proliferative peptides and their use as pharmaceutic and phytopharmaceutic agents
US5955573A (en) 1993-06-04 1999-09-21 Demegen, Inc. Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
AU1086595A (en) 1993-11-08 1995-05-29 Demeter Biotechnologies, Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
IL114697A0 (en) * 1994-07-22 1995-11-27 Demeter Biotech Ltd Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use
AU4602897A (en) 1996-10-04 1998-04-24 Demegen, Inc. Method for treatment of immunodeficiency virus infection
DE19711831C2 (de) 1997-03-21 2000-07-13 Daimler Chrysler Ag Schmelzinfiltrierte faserverstärkte Verbundkeramik und Verfahren zur Herstellung einer solchen
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
AU6587998A (en) * 1997-03-27 1998-10-20 Demeter Biotechnologies, Ltd. Ligand/lytic peptide compositions and methods of use
WO2002079408A2 (en) 2001-03-28 2002-10-10 Helix Biomedix, Inc. Short bioactive peptides and methods for their use
US7091185B2 (en) * 2003-02-24 2006-08-15 Dow Global Technologies Inc. Periodic antimicrobial peptides
GB0326393D0 (en) 2003-11-12 2003-12-17 Ares Trading Sa Cytokine antagonist molecules
US7288622B1 (en) * 2006-09-19 2007-10-30 Issar Pharmaceuticals Pvt Ltd Composition for treatment of burns and wounds
US7803755B2 (en) 2006-12-21 2010-09-28 Jesse Jaynes Molecules for the treatment and prevention of fungal diseases
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
WO2012050892A2 (en) * 2010-09-29 2012-04-19 Esperance Pharmaceuticals, Inc. Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors
US8734775B2 (en) 2011-08-26 2014-05-27 University Of Pittsburgh Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
US9487560B2 (en) 2013-05-02 2016-11-08 ISSAR Pharmaceuticals Ltd Angiogenic active lytic peptides
CA2964361A1 (en) * 2014-10-14 2016-04-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Peptide-based methods for treating pancreatic cancer
US9737584B2 (en) * 2015-08-11 2017-08-22 Issar Pharmaceuticals Composition for the treatment of burns, diabetic wounds, other types of wounds and subsequently greatly reduced scarring

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003749A1 (en) * 1991-08-21 1993-03-04 Board Of Regents, The University Of Texas System Methods and compositions for modulating g protein action
WO1995028832A1 (en) * 1994-04-20 1995-11-02 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
CN1377276A (zh) * 1999-08-09 2002-10-30 特里帕普股份公司 含有三肽的药用组合物
CN101485885A (zh) * 2009-01-09 2009-07-22 中国科学院广州生物医药与健康研究院 蛋白磷酸酯酶PPM1E作为疾病的治疗靶标及其应用和siRNA
US20120270770A1 (en) * 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
YU FU WANG ET AL.: "A Cell-penetrating Peptide Suppresses Inflammation by Inhibiting NF-KB Signaling", 《MOLECULAR THERAPY》 *
刘冬妍等: "TNF-α对肠上皮细胞PIgR、NF-KB亚单位表达影响", 《中国免疫学杂志》 *
张惠展: "《基因工程》", 31 August 2005, 华东理工大学出版社 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109745324A (zh) * 2017-11-06 2019-05-14 中国科学院上海生命科学研究院 非经典NF-kB通路的小分子抑制剂及其应用
CN112840211A (zh) * 2018-08-27 2021-05-25 南特生物公司 Rp182组合物及方法
US12385903B2 (en) 2018-08-27 2025-08-12 Nantbio, Inc. RP182 compositions and methods
CN114207117A (zh) * 2019-04-12 2022-03-18 激流生物科学有限公司 用于调节巨噬细胞活性的方法
CN115838395A (zh) * 2022-11-15 2023-03-24 西北农林科技大学 具有可溶性环氧化物水解酶抑制作用的活性肽及其应用
CN118530299A (zh) * 2023-08-25 2024-08-23 广州益养生物科技有限公司 一种三肽、三肽盐或衍生物及其应用

Also Published As

Publication number Publication date
WO2016061133A1 (en) 2016-04-21
CN107580502B (zh) 2020-10-30
CN107580502A (zh) 2018-01-12
WO2016061087A1 (en) 2016-04-21
AU2015333678A1 (en) 2017-04-27
EP3206703A1 (en) 2017-08-23
KR20170070152A (ko) 2017-06-21
US20190046601A1 (en) 2019-02-14
JP2017537141A (ja) 2017-12-14
EP3206703B1 (en) 2021-05-19
US20170252396A1 (en) 2017-09-07
AU2015333678B2 (en) 2020-05-14
NZ730865A (en) 2024-02-23
CA2963478A1 (en) 2016-04-21
ZA201702537B (en) 2020-10-28
US20170020956A1 (en) 2017-01-26
EP3206704A1 (en) 2017-08-23
KR102478073B1 (ko) 2022-12-16
US20210077566A1 (en) 2021-03-18
US10149886B2 (en) 2018-12-11
JP6613312B2 (ja) 2019-11-27
US10016480B2 (en) 2018-07-10
JP2020180149A (ja) 2020-11-05
CA2964361A1 (en) 2016-04-21
US9492499B2 (en) 2016-11-15
KR20170078689A (ko) 2017-07-07
JP7023709B2 (ja) 2022-02-22
KR20230004907A (ko) 2023-01-06
EP3206704A4 (en) 2018-10-17
JP2018503668A (ja) 2018-02-08
AU2015333728B2 (en) 2020-07-30
AU2015333728A1 (en) 2017-05-18
EP3206704B1 (en) 2022-04-20
US20160101150A1 (en) 2016-04-14
BR112017007543A2 (pt) 2017-12-19

Similar Documents

Publication Publication Date Title
CN107106638A (zh) 具有抗炎特性的肽
Tao et al. A dual-targeted metal–organic framework based nanoplatform for the treatment of rheumatoid arthritis by restoring the macrophage niche
CN104127879A (zh) 结合SPARC的scFv
CN107106655A (zh) 使用白细胞介素‑10治疗疾病和病症的方法
CN112771067A (zh) 包含基于SIRPα的嵌合蛋白的组合疗法
CN110381974A (zh) 基于csf1r的嵌合蛋白
AU2016227322A1 (en) Dual signaling protein (DSP) fusion proteins, and methods of using thereof for treating diseases
JP2022512540A (ja) Ｆｌｔ３ｌ系キメラタンパク質
CN118184797A (zh) 基于vsig8的嵌合蛋白
EP3962526A1 (en) Anti-lag-3 binding molecules
US20210401927A1 (en) Peptides Having Immunomodulatory Properties
US20220143130A1 (en) Peptides Having Immunomodulatory Properties
EP3844297A2 (en) Peptides having immunomodulatory properties
EP3762013A2 (en) A therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
HK1242985A1 (en) Peptides having anti-inflammatory properties
ES2776243T3 (es) Un polipéptido de dímero CCL20 bloqueado modificado por ingeniería
JP2025533403A (ja) 標的化ｐｄ－ｌ１分解
WO2025032571A1 (en) Unit dosage forms and methods comprising bl8040 for intravenous administration
WO2023097111A2 (en) Methods and compositions for treating calcinosis associated conditions
HK40023893A (en) Tgf-beta receptor type ii fusion proteins and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1242985

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1242985

Country of ref document: HK